Physician profile
Kelly Liang
NPI 1013771922
$575.17
in general payments reported to CMS, 2019-2025
14 companies · $575 in 2025
The $575 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $140.91 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $113.36 | 2025 | |
| Janssen Biotech, INC. | $48.25 | 2025 | Erleada, Darzalex, Talvey |
| Astellas Pharma US INC | $48.14 | 2025 | Xtandi, Vyloy |
| Tersera Therapeutics LLC | $33.69 | 2025 | Zoladex |
| Sobi, INC | $29.39 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.27 | 2025 | Iclusig |
| Geron Corporation | $27.61 | 2025 | Rytelo |
| Emd Serono, INC. | $26.70 | 2025 | |
| Merck Sharp & Dohme LLC | $23.14 | 2025 | Keytruda Qlex, Keytruda |
| Astrazeneca Pharmaceuticals Lp | $19.31 | 2025 | |
| Pfizer INC. | $18.78 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.62 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.